Institute of Human Genetics, Medical School, Saarland University, Building 60, 66421 Homburg/Saar, Germany.
BMC Cancer. 2010 Jun 7;10:262. doi: 10.1186/1471-2407-10-262.
MicroRNA (miRNA) signatures are not only found in cancer tissue but also in blood of cancer patients. Specifically, miRNA detection in blood offers the prospect of a non-invasive analysis tool.
Using a microarray based approach we screened almost 900 human miRNAs to detect miRNAs that are deregulated in their expression in blood cells of melanoma patients. We analyzed 55 blood samples, including 20 samples of healthy individuals, 24 samples of melanoma patients as test set, and 11 samples of melanoma patients as independent validation set.
A hypothesis test based approach detected 51 differentially regulated miRNAs, including 21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients as compared to blood cells of healthy controls. The tets set and the independent validation set of the melanoma samples showed a high correlation of fold changes (0.81). Applying hierarchical clustering and principal component analysis we found that blood samples of melanoma patients and healthy individuals can be well differentiated from each other based on miRNA expression analysis. Using a subset of 16 significant deregulated miRNAs, we were able to reach a classification accuracy of 97.4%, a specificity of 95% and a sensitivity of 98.9% by supervised analysis. MiRNA microarray data were validated by qRT-PCR.
Our study provides strong evidence for miRNA expression signatures of blood cells as useful biomarkers for melanoma.
微小 RNA(miRNA)特征不仅存在于癌症组织中,也存在于癌症患者的血液中。具体来说,miRNA 在血液中的检测提供了一种非侵入性分析工具的前景。
我们使用基于微阵列的方法筛选了近 900 个人类 miRNA,以检测在黑色素瘤患者血细胞中表达失调的 miRNA。我们分析了 55 个血液样本,包括 20 个健康个体样本、24 个黑色素瘤患者测试集样本和 11 个黑色素瘤患者独立验证集样本。
基于假设检验的方法检测到 51 个差异调节的 miRNA,包括 21 个在黑色素瘤患者血细胞中下调的 miRNA 和 30 个在黑色素瘤患者血细胞中上调的 miRNA,与健康对照组相比。测试集和黑色素瘤样本的独立验证集显示出较高的折叠变化相关性(0.81)。通过层次聚类和主成分分析,我们发现基于 miRNA 表达分析,可以很好地区分黑色素瘤患者和健康个体的血液样本。通过使用 16 个显著失调 miRNA 的子集,我们通过监督分析实现了 97.4%的分类准确率、95%的特异性和 98.9%的敏感性。miRNA 微阵列数据通过 qRT-PCR 进行验证。
我们的研究为血液细胞的 miRNA 表达特征作为黑色素瘤的有用生物标志物提供了有力证据。